In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite

Biomaterials

Volumn 31, Issue 30, 2010, Pages 7776-7784

  Verron, Elise ^a,d   Gauthier, Olivier ^a,b   Janvier, Pascal ^c   Pilet, Paul ^a   Lesoeur, Julie ^a   Bujoli, Bruno ^c   Guicheux, Jerome ^a   Bouler, Jean Michel ^a  

^a Universite de Nantes   (France)

^b LUNAM UNIVERSITÉ   (France)

^c Centre National de la Recherche Scientifique   (France)

^d Graftys SA   (France)

Author keywords

Animal model; Bone regeneration; Calcium phosphates; Drug delivery; Osteoporosis

Indexed keywords

ANIMAL MODEL; BISPHOSPHONATES; BONE AUGMENTATION; BONE MICROARCHITECTURE; BONE REGENERATION; BONE RESORPTION; BONE STRUCTURE; CALCIUM DEFICIENT APATITES; CLINICAL TREATMENTS; IN-VITRO; IN-VIVO; MATRIX; MICRO ARCHITECTURES; MICRO-TOMOGRAPHY; OSTEOPOROSIS; OSTEOPOROTIC; OSTEOPOROTIC FRACTURES; PROXIMAL FEMUR; RAT MODEL; RECONSTRUCTIVE SURGERY; RESORBABLE; SEM OBSERVATION; VERTEBRAL BODY;

ARCHITECTURE; BIOLOGICAL MATERIALS; BIOMATERIALS; CALCIUM; CALCIUM PHOSPHATE; DRUG DELIVERY; GRAFTS; MAMMALS; PHOSPHATE MINERALS; THREE DIMENSIONAL;

BONE;

APATITE; BIOMATERIAL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM PHOSPHATE; HYDROXYPROPYLMETHYLCELLULOSE; UNCLASSIFIED DRUG; ZOLEDRONATE CALCIUM DEFICIENT APATITE CONJUGATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MINERAL; BONE REGENERATION; BONE REMODELING; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EWE; FEMALE; FEMUR; HISTOPATHOLOGY; HYDROGEL; IMAGE ANALYSIS; IMPLANT; IN VIVO STUDY; INJECTION; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; THREE DIMENSIONAL IMAGING; TOMOGRAPHY; TRABECULAR BONE;

ANIMALS; APATITES; BIOCOMPATIBLE MATERIALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM; DIPHOSPHONATES; DRUG CARRIERS; FEMALE; FEMUR; HUMANS; IMPLANTS, EXPERIMENTAL; MATERIALS TESTING; OSTEOPOROSIS; OVARIECTOMY; RATS; RATS, WISTAR; SHEEP;

ANIMALIA; RATTUS;

EID: 77955773606     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.06.047     Document Type: Article

References (62)

1. Consensus development.conference. diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993, 94(6):646-650.
2. Melton L.J., Chrischilles E.A., Cooper C., Lane A.W., Riggs B.L. Perspective. How many women have osteoporosis?. J Bone Miner Res 1992, 7(9):1005-1010.
3. Jones G., Nguyen T., Sambrook P.N., Kelly P.J., Gilbert C., Eisman J.A. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 1994, 4(5):277-282.
4. Klotzbuecher C.M., Ross P.D., Landsman P.B., Abbott T.A., Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15(4):721-739.
5. Ensrud K.E., Thompson D.E., Cauley J.A., Nevitt M.C., Kado D.M., Hochberg M.C., et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 2000, 48(3):241-249.
6. Van Balen R., Steyerberg E.W., Polder J.J., Ribbers T.L., Habbema J.D., Cools H.J. Hip fracture in elderly patients: outcomes for function, quality of life, and type of residence. Clin Orthop Relat Res 2001, 390:232-243.
7. Fulfaro F., Casuccio A., Ticozzi C., Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998, 78(3):157-169.
8. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88(Suppl. 12):2961-2978.
9. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13(4):581-589.
10. Fisher J.E., Rodan G.A., Reszka A.A. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000, 141(12):4793-4796.
11. Reszka A.A., Halasy-Nagy J.M., Masarachia P.J., Rodan G.A. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999, 274(49):34967-34973.
12. McClung M.R. Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother 2000, 1(2):225-238.
13. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350(12):1189-1199.
14. Papapoulos S.E., Quandt S.A., Liberman U.A., Hochberg M.C., Thompson D.E. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005, 16(5):468-474.
15. Orcel P. Prevention and treatment of glucocorticoid-induced osteoporosis in 2005. Jt Bone Spine 2005, 72(6):461-465.
16. Gallagher A.M., Rietbrock S., Olson M., van Staa T.P. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008, 23(10):1569-1575.
17. Huybrechts K.F., Ishak K.J., Caro J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006, 38(6):922-928.
18. McCombs J.S., Thiebaud P., McLaughlin-Miley C., Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004, 48(3):271-287.
19. Rabenda V., Vanoverloop J., Fabri V., Mertens R., Sumkay F., Vannecke C., et al. Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Jt Surg Am 2008, 90(10):2142-2148.
20. Rabenda V., Mertens R., Fabri V., Vanoverloop J., Sumkay F., Vannecke C., et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008, 19(6):811-818.
21. Siris E.S., Harris S.T., Rosen C.J., Barr C.E., Arvesen J.N., Abbott T.A., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006, 81(8):1013-1022.
22. Emkey R.D., Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006, 119(4 Suppl. 1):S18-S24.
23. Cramer J.A., Gold D.T., Silverman S.L., Lewiecki E.M. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007, 18(8):1023-1031.
24. Ransford A., Morley T., Edgar M., Webb P., Passuti N., Chopin D., et al. Synthetic porous ceramic compared with autograft in scoliosis surgery. A prospective, randomized study of 341 patients. J Bone Jt Surg Br 1998, 80(1):13-18.
25. Cavagna R., Daculsi G., Bouler J.M. Macroporous calcium phosphate ceramic: a prospective study of 106 cases in lumbar spinal fusion. J Long Term Eff Med Implants 1999, 9(4):403-412.
26. Aulakh T.S., Jayasekera N., Kuiper J.H., Richardson J.B. Long-term clinical outcomes following the use of synthetic hydroxyapatite and bone graft in impaction in revision hip arthroplasty. Biomaterials 2009, 30(9):1732-1738.
27. Roussière H., Fayon F., Alonso B., Rouillon T., Schnitzler V., Verron E., et al. Reaction of zoledronate with b-Tricalcium phosphate for the design of potential drug device combined systems. Chem Mater 2008, 20:182-191.
28. Josse S., Faucheux C., Soueidan A., Grimandi G., Massiot D., Alonso B., et al. Novel biomaterials for bisphosphonate delivery. Biomaterials 2005, 26(14):2073-2080.
29. Josse S., Faucheux C., Grimandi G., Massiot A., Alonso B., Janvier P., et al. An innovative strategy for local treatment of bone resorption and prevention of osteoporotic fractures. Adv Mater 2004, 16(16):1423-1427.
30. Roussière H., Montavon G., Laïb S., Janvier P., Alonso B., Fayon F., et al. Hybrid materials applied to biotechnologies: coating of calcium phosphates for the design of implants active against bone resorption disorders. J Mater Chem 2005, 15:3869-3875.
31. Faucheux C., Verron E., Soueidan A., Josse S., Arshad M.D., Janvier P., et al. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J Biomed Mater Res A 2008, 46-56.
32. Peter B., Gauthier O., Laib S., Bujoli B., Guicheux J., Janvier P., et al. Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. J Biomed Mater Res A 2006, 76(1):133-143.
33. Bobyn J.D., McKenzie K., Karabasz D., Krygier J.J., Tanzer M. Locally delivered bisphosphonate for enhancement of bone formation and implant fixation. J Bone Jt Surg Am 2009, 91(Suppl. 6):23-31.
34. Peter B., Pioletti D.P., Laib S., Bujoli B., Pilet P., Janvier P., et al. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone 2005, 36(1):52-60.
35. Cesareo R., Iozzino M., Alva D., Napolitano C., De Rosa B., Contini S., et al. Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures. Minerva Endocrinol 2007, 32(4):275-295.
36. Cranney A., Jamal S.A., Tsang J.F., Josse R.G., Leslie W.D. Low bone mineral density and fracture burden in postmenopausal women. Can Med Assoc J 2007, 177(6):575-580.
37. Kannus P., Parkkari J., Niemi S., Pasanen M., Palvanen M., Jarvinen M., et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 2000, 343(21):1506-1513.
38. Owens G., Jackson R., Lewiecki E.M. An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 2007, 13(Suppl. 11):S290-S308. quiz S309-S312.
39. Quigley P.A., Bulat T., Hart-Hughes S. Strategies to reduce risk of fall-related injuries in rehabilitation nursing. Rehabil Nurs 2007, 32(3):120-125.
40. Tang B.M., Eslick G.D., Nowson C., Smith C., Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007, 370(9588):657-666.
41. Dinah A.F. Sequential hip fractures in elderly patients. Injury 2002, 33(5):393-394.
42. Beckmann J., Ferguson S.J., Gebauer M., Luering C., Gasser B., Heini P. Femoroplasty-augmentation of the proximal femur with a composite bone cement-feasibility, biomechanical properties and osteosynthesis potential. Med Eng Phys 2007, 29(7):755-764.
43. Van der Steenhoven T.J., Schaasberg W., de Vries A.C., Valstar E.R., Nelissen R.G. Augmentation with silicone stabilizes proximal femur fractures: an in vitro biomechanical study. Clin Biomech 2009, 24(3):286-290.
44. Heini P.F., Franz T., Fankhauser C., Gasser B., Ganz R. Femoroplasty-augmentation of mechanical properties in the osteoporotic proximal femur: a biomechanical investigation of PMMA reinforcement in cadaver bones. Clin Biomech 2004, 19(5):506-512.
45. Obadia L., Rouillon T., Bujoli B., Daculsi G., Bouler J. Calcium-deficient apatite synthesized by ammonia hydrolysis of dicalcium phosphate dihydrate: influence of temperature, time, and pressure. J Biomed Mater Res B Appl Biomater 2007, 80(1):32-42.
46. Ishikawa K., Ducheyne P., Radin S. Determination of the Ca/P ratio in calcium deficient hydroxyapatite using X-ray diffraction analysis. J Mater Sci Mater Med 1993, 4:165-168.
47. Stadelmann V.A., Gauthier O., Terrier A., Bouler J.M., Pioletti D.P. Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study. Eur Cell Mater 2008, 16:10-16.
48. Stadelmann V.A., Terrier A., Gauthier O., Bouler J.M., Pioletti D.P. Prediction of bone density around orthopedic implants delivering bisphosphonate. J Biomech 2009, 42(9):1206-1211. 19.
49. Parfitt A., Mathews C., Villanueva A., Kleerekoper M., Frame B., Rao D. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 1983, 72(4):1396-1409.
50. Muller R., Van Campenhout H., Van Damme B., Van Der Perre G., Dequeker J., Hildebrand T., et al. Morphometric analysis of human bone biopsies: a quantitative structural comparison of histological sections and micro-computed tomography. Bone 1998, 23(1):59-66.
51. Russell R. Ibandronate: Pharmacology and preclinical studies. Bone 2006, 38:S7-S12.
52. Kalu D. The ovariectomized rat model of postmenopausal bone loss. Bone Miner 1999, 15:175-192.
53. Frost H.M., Jee W.S. On the rat model of human osteopenias and osteoporoses. Bone Miner 1992, 18(3):227-236.
54. Erben R.G., Mosekilde L., Thomsen J.S., Weber K., Stahr K., Leyshon A., et al. Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3. J Bone Miner Res 2002, 17(8):1498-1511.
55. Ito M., Azuma Y., Takagi H., Kamimura T., Komoriya K., Ohta T., et al. Preventive effects of sequential treatment with alendronate and 1 alpha-hydroxyvitamin D3 on bone mass and strength in ovariectomized rats. Bone 2003, 33(1):90-99.
56. Jiang G., Matsumoto H., Yamane J., Kuboyama N., Akimoto Y., Fujii A. Prevention of trabecular bone loss in the mandible of ovariectomized rats. J Oral Sci 2004, 46(2):75-85.
57. Turner A.S., Alvis M., Myers W., Stevens M.L., Lundy M.W. Changes in bone mineral density and bone-specific alkaline phosphatase in ovariectomized ewes. Bone 1995, 17(Suppl. 4):395S-402S.
58. Turner A.S., Mallinckrodt C.H., Alvis M.R., Bryant H.U. Dose-response effects of estradiol implants on bone mineral density in ovariectomized ewes. Bone 1995, 17(Suppl. 4):421S-427S.
59. Chavassieux P., Garnero P., Duboeuf F., Vergnaud P., Brunner-Ferber F., Delmas P.D., et al. Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric study. J Bone Miner Res 2001, 16(1):89-96.
60. Newton B.I., Cooper R.C., Gilbert J.A., Johnson R.B., Zardiackas L.D. The ovariectomized sheep as a model for human bone loss. J Comp Pathol 2004, 130(4):323-326.
61. Khairoun I, Gauthier O, Fellah F, Weiss P, Bouler JM. In vitro and in vivo studies of an injectable calcium phosphate cement for biomedical applications. In: 8th World Biomaterials Congress, 2008, Amsterdam; 2008.
62. Khairoun I, Fellah B, Gauthier O, Weiss P, Bouler JM. Comparison between two calcium phosphate cements: in vitro and preclinical evaluation study. In: 19th GRIBOI Interdisciplinary Research Conference on Biomaterials, 2009 March 25th-27th, Fort de France, French West Indies; 2009.